Solid Biosciences (SLDB) stock
Follow SLDB's trial news. Pro members can get an alert when Solid Biosciences files news, and see its trials, share raises, and its CEO's filings.
What's next for SLDB, and how long its cash lasts
From Solid Biosciences’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Its trials
Cash runway
About 8 quarters
Dilution on the horizon
- Shelf registration (S-3ASR, filed Aug 6, 2026)
- At-the-market share sales program (424B5, filed Aug 6, 2026)
Insiders
CEO Alexander Cumbo sold 16,644 shares on Feb 18, under a planned sale. 21 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 28 daysINOInovio Pharmaceuticals
INOINO-3107
- In 39 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 51 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 29% in 3 months, 18% under its 50-day average.
Down more than its industry: the 275 other stocks in it fell a median 11% over the same 3 months.
−1Profit Lost $174M in the year to Dec 31, 2025, more than the $125M lost the year before, from the SEC filing
1 more thing pulling SLDB's score down, for Pro members
What's next
Expected to report Mon Nov 2, after the close
After its last 2 reports it closed +1.8% on average, higher 1 of 2 times.
Wed Nov 11: BioPharma Cell & Gene Therapy Nexus 2026Industry event · date confirmed.
What would turn SLDB's score around: 6 things, for Pro members
Here is what Pro members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
SLDB has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1430.3
- MACD (12, 26, 9)Below signal
- 50-day average$8.77
- 200-day average$7.58
- ADX 1429.7
- Support$6.76
- Resistance$7.33
- Bollinger Bands (20, 2)Inside
- Volume1.2x
How SLDB ranks in Biotech
SLDB is #146 of 276 by Quality Score. The top three are shown with their scores, and more by name.
KNSA7/1418
ABCL6/1416
OABI9/1415
SGMTOpen for its score
SIONOpen for its score
SMMTOpen for its score
SRPTOpen for its score
SLDB1/14-1
When does SLDB report earnings, and what happens after?
Expected to report Mon Nov 2, after the close (in 31 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Mar 6, 2026After close | After close | +2.2% | +18.8% | +8.3% |
| Nov 3, 2025After close | After close | -9.4% | -15.3% | -20.2% |
About Solid Biosciences
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of SLDB's score, with the points and the reason
- All 14 checks on SLDB and on all 2,958 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on SLDB
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.